Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma

MAPKAPK2 (MK2), the direct substrate of p38 MAPK, has been well-acknowledged as an attractive drug target for cancer therapy. However, few studies have assessed the functions of it in multiple myeloma (MM). In the present study, MK2 expression of MM patients was analyzed by gene expression profiling...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Mengjie, Sun, Dongdong, Fan, Zhimin, Yuan, Yuxia, Shao, Miaomiao, Hou, Jianhao, Zhu, Yuqi, Wei, Rongfang, Zhu, Yan, Qian, Jinjun, Li, Fei, Yang, Ye, Gu, Chunyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694709/
https://www.ncbi.nlm.nih.gov/pubmed/31440466
http://dx.doi.org/10.3389/fonc.2019.00722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694709/
https://www.ncbi.nlm.nih.gov/pubmed/31440466
http://dx.doi.org/10.3389/fonc.2019.00722

Ejemplares similares